Aquinox Pharmaceutic (AQXP) 12.24 $AQXP Aquinox

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aquinox Pharmaceutic (AQXP) 12.24 $AQXP

Aquinox Pharmaceuticals Announces Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:15PM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update and reported financial results for the second quarter ending June 30, 2016.
AQXP: 12.24 (+1.62)

Aquinox Pharmaceuticals to Announce Second Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 01, 8:20AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will report its financial results for the second quarter ending June 30, 2016 and will provide a general business update on Thursday, August 4, 2016 after U.S. financial markets close. Aquinox will host a conference call and live audio webcast on Thursday, August 4, 2016 at 4:30 PM (ET) / 1:30 PM (PT).
AQXP: 12.24 (+1.62)

Aquinox to Present at Canaccord Genuity 36th Annual Growth Conference
GlobeNewswire - Mon Aug 01, 8:15AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming Canaccord Genuity 36th Annual Growth Conference in Boston, MA on Thursday, August 112016 at 1:00 PM Eastern Time.
AQXP: 12.24 (+1.62)

Aquinox to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 8:15AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that Kamran Alam, Aquinox Vice President of Finance & CFO, will present a corporate overview at the upcoming Jefferies 2016 Healthcare Conference in New York city on Thursday, June 92016 at 8:00 AM Eastern Time.
AQXP: 12.24 (+1.62)

Aquinox Announces Executive Appointments
GlobeNewswire - Wed May 25, 8:15AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Mrs. Abigail L. Jenkins as Chief Commercial Officer and Mr. Paul Brennan as Vice President, Business Development. Mrs. Jenkins will act as our US Business Head at our San Bruno, CA office and lead the design and implementation of the commercialization strategy for AQX-1125 while Mr. Brennan will be responsible for the identification and fostering of corporate alliances to support and compliment our global business strategies.
ACT: 298.98 (-2.94), AQXP: 12.24 (+1.62), PFE: 34.68 (-0.12)

Aquinox to Present at 2016 Annual UBS Global Healthcare Conference
GlobeNewswire - Wed May 18, 8:15AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming 2016 Annual UBS Global Healthcare Conference in New York city on Wednesday, May 252016 at 11:00 AM Eastern Time.
AQXP: 12.24 (+1.62)

Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 8:05AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update and reported financial results for the first quarter ending March 31, 2016.
AQXP: 12.24 (+1.62)

Aquinox to Present at 2016 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire - Thu Apr 28, 8:16AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming 2016 Annual Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, May 32016 at 11:30 AM Eastern Time.
AQXP: 12.24 (+1.62)

Aquinox to Present at 2016 Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 8:15AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming 15 Annual Needham Healthcare Conference in New York city on Wednesday, April 13, 2016 at 12:10 PM Eastern Time.
AQXP: 12.24 (+1.62)

Global Asthma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdlwml/asthma_pipeline) has announced the addition of the "Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Asthma Overview - Therapeutics Development - Pipeline Products for Asthma - Overview - Pipeline Products for Asthma - Comparative Analysis - Asthma - Therapeutics under Development by Companies - Asthma - Therapeutics under Investigation by Universities/Institutes - Asthma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Asthma - Products under Development by Companies - Asthma - Products under Investigation by Universities/Institutes - Asthma - Companies Involved in Therapeutics Development Companies Featured - Partial List - 4D Pharma Plc - AB Science SA - Abeome Corporation - Accolade Pharma LLC - Acorda Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - Afferent Pharmaceuticals, Inc. - AFFiRiS AG - Alba Therapeutics Corporation - ALK-Abello A/S - Allergopharma GmbH & Co. KG - Amakem NV - Amgen Inc. - AnaptysBio, Inc. - Antisense Therapeutics Limited - Aquinox Pharmaceuticals Inc. - ARA Healthcare Pvt. Ltd. - Ario Pharma Ltd - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Aurigene Discovery Technologies Limited - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Biokine Therapeutics Ltd. - BioLineRx, Ltd. - Bioncotech Therapeutics S.L. - Biotec Pharmacon ASA - BioTech Tools s.a. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - CalciMedica, Inc. For more information visit http://www.researchandmarkets.com/research/wd...a_pipeline
AQXP: 12.24 (+1.62), ADMP: 2.81 (-0.14), AMGN: 170.13 (+0.07), ACOR: 24.34 (+0.26), CLBS: 4.83 (-0.01), AZN: 32.60 (-0.21), ARRY: 3.52 (+0.09)

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review - Companies Mentioned Include Afferent Pharmaceuticals, Allergan Plc & Qu Biologics Inc
M2 - Fri Jan 29, 2:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv59zp/interstitial) has announced the addition of the "Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Afferent Pharmaceuticals, Inc. - Allergan Plc - Aquinox Pharmaceuticals Inc. - Kytogenics Pharmaceuticals, Inc. - Lipella Pharmaceuticals, Inc. - MediPost Co., Ltd. - Qu Biologics Inc. - Urigen Pharmaceuticals, Inc. Key Topics Covered: - Introduction - Interstitial Cystitis (Painful Bladder Syndrome) Overview - Therapeutics Development - Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview - Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis - Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies - Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes - Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies - Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes - Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development Companies Mentioned: - Afferent Pharmaceuticals, Inc. - Allergan Plc - Aquinox Pharmaceuticals Inc. - Kytogenics Pharmaceuticals, Inc. - Lipella Pharmaceuticals, Inc. - MediPost Co., Ltd. - Qu Biologics Inc. - Urigen Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/bv...terstitial
AGN: 237.76 (+3.22), AQXP: 12.24 (+1.62)

Aquinox to Present at LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Thu Jan 28, 8:15AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming LEERINK Partners 5th Annual Global Healthcare Conference in New York city on Thursday, February 112016 at 1:50 PM Eastern Time.
AQXP: 12.24 (+1.62)

World Atopic Dermatitis Therapeutics Pipeline Report 2015
M2 - Thu Jan 14, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmkzdg/atopic_dermatitis) has announced the addition of the "Atopic Dermatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Atopic Dermatitis Overview - Therapeutics Development - Pipeline Products for Atopic Dermatitis - Overview - Pipeline Products for Atopic Dermatitis - Comparative Analysis - Atopic Dermatitis - Therapeutics under Development by Companies - Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes - Atopic Dermatitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Atopic Dermatitis - Products under Development by Companies - Atopic Dermatitis - Products under Investigation by Universities/Institutes - Atopic Dermatitis - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - Abeome Corporation - AlbireoPharma - Almirall, S.A. - Amgen Inc. - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Celgene Corporation - ChemoCentryx, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Creabilis SA - Delenex Therapeutics AG - Dermira Inc. - Dr. August Wolff GmbH & Co. KG Arzneimittle - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline Plc - Glenmark Pharmaceuticals Ltd. - Grupo Ferrer Internacional, S.A. - Han Wha Pharma Co., Ltd. - HanAll Biopharma Co., Ltd. - Herantis Pharma Plc - iCo Therapeutics Inc. - IMMD Inc. - Immune Pharmaceuticals Inc. - Inflamalps SA For more information visit http://www.researchandmarkets.com/research/zm...dermatitis
AQXP: 12.24 (+1.62), FOMX: 8.67 (+0.37), AMGN: 170.13 (+0.07), IMNP: 0.34 (+0.01), GSK: 42.98 (-0.48), DERM: 32.22 (+1.18), CCXI: 5.29 (+0.29), ANAC: 99.06 (-0.14), CELGZ: 1.13 (-0.03)

Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
GlobeNewswire - Mon Jan 11, 6:00AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced receipt of official minutes from its December 8, 2015 meeting with the Division of Bone, Reproductive and Urologic Products (DBRUP) of the United States Food and Drug Administration (FDA) and provided an update on its plans for development of AQX-1125 for the treatment of patients with bladder pain syndrome/interstitial cystitis (BPS/IC). Discussed at the meeting were guidance and recommendations regarding proposed pivotal trial designs with AQX-1125 for BPS/IC, as well as additional supportive clinical, preclinical and manufacturing activities that could potentially be required for registration.
AQXP: 12.24 (+1.62)

Innovation Sparks Advancement of New Treatments for Atopic Dermatitis
ACCESSWIRE - Thu Jan 07, 8:25AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 7, 2016 / Even though the root cause of atopic dermatitis (AD), or eczema, remains a mystery, this is an exciting time in the dermatology space with innovation driving substantial advancements for the first time in decades. As Peter Lio, MD, assistant professor of clinical dermatology and pediatrics-dermatology at Northwestern University Feinberg School of Medicine, explained in the October edition of The Dermatologist, part of the challenge rests in the fact that a range of factors play a role in the immunopathogenesis of AD, a chronic, itchy inflammation of the skin that can range from mild to severe.
AQXP: 12.24 (+1.62), VNDA: 15.29 (-0.09), VTAE: 6.84 (-0.07), OCLS: 4.13 (+0.04)

Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
GlobeNewswire - Tue Dec 22, 8:15AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Ms. Shelley McCloskey as Vice President of Human Resources & Administration. Ms. McCloskey has joined the Executive team to help guide the continued growth and development of the Company.
AQXP: 12.24 (+1.62)

Aquinox Selected for Addition to NASDAQ Biotechnology Index
GlobeNewswire - Wed Dec 16, 8:15AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that it has been selected for addition to the NASDAQ Biotechnology Index effective prior to market open on Monday, December 21, 2015.
AQXP: 12.24 (+1.62)

Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gd4hqf/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Aquinox Pharmaceuticals Inc. - Ardelyx, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Connexios Life Sciences Pvt. Ltd. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - DURECT Corporation - Dynavax Technologies Corporation - Enanta Pharmaceuticals, Inc. - Exicure, Inc. - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - iCo Therapeutics Inc. - Merck & Co., Inc. - Mochida Pharmaceutical Co., Ltd. - NGM Biopharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Novartis AG - Novo Nordisk A/S - Protalix BioTherapeutics, Inc. - Regulus Therapeutics Inc. - RuiYi Inc. - Shire Plc - Vascular Biogenics Ltd. - Verva Pharmaceuticals Limited - Viking Therapeutics, Inc. - Virobay Inc. - Zafgen Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/gd...nalcoholic
DVAX: 15.94 (+0.28), ZFGN: 3.04 (+0.05), AQXP: 12.24 (+1.62), GALT: 1.65 (-0.07), RGLS: 3.16 (-0.01), BMY: 56.76 (-0.63), DRRX: 1.61 (-0.06), ENTA: 22.02 (+0.03), NVO: 46.34 (-0.38), GILD: 77.42 (-0.96), SHPG: 188.50 (+1.32), MRK: 62.90 (+0.11), VBAY: (), VBLT: 4.06 (-0.05), VKTX: 1.30 (-0.04), NVS: 78.27 (-0.50)

Aquinox to Participate in Two Upcoming Investor Events
GlobeNewswire - Thu Dec 10, 8:15AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox" (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that senior management will be meeting with investors at two upcoming investor events.
AQXP: 12.24 (+1.62)

Beyond the Chart, What Price Data Reveals - Research on Endochoice Holdings, Catalyst Pharmaceuticals, Aquinox Pharmaceuticals and ARC Document Solutions
ACCESSWIRE - Thu Nov 19, 7:45AM CST
NEW YORK, NY / ACCESSWIRE / November 19, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Endochoice Holdings Inc. (NYSE: GI), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) and ARC Document Solutions Inc. (NYSE: ARC). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ARC: 3.39 (+0.01), AQXP: 12.24 (+1.62), CPRX: 0.96 (-0.05), GI: 3.89 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 67

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 33

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 44

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
KuCoin Unveils $1.1M USDT Black Friday Bonanza

Updated Category News Views 0

KuCoin's Festive Fireworks: Black Friday Bonanza Sometimes the crypto world feels like a carnival, and KuCoin's latest act is the $1.1 million USDT prize pool, rolling out as part of its 'Tis The Season holiday campaign. A move that matches the glitz of Tomorrowland Winter experiences, adding more sparkle to the crypto stage. Behind the Scenes of the KuCoin-Tomorrowland...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 25

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading

Top 5 Most Recently Viewed Articles

Carota Unveils Innovative MaaS Service to Transform Mobility

Updated Category News Views 248

Carota Announces Launch of Transformative MaaS Service In a significant move for the transportation sector, Carota has introduced its innovative MaaS (Mobility as a Service) smart mobility service. This decision comes as a response to the rapid changes in global mobility services, highlighting Carota's commitment to adapting and evolving to meet the needs of the modern...

Continue Reading
Fossil Group Sees Growth with Strong Q2 2025 Financials

Updated Category News Views 185

Fossil Group's Financial Performance in Q2 2025 Fossil Group, Inc. (NASDAQ: FOSL) has announced its financial results for the second quarter of 2025, showcasing significant progress amid a fluctuating market landscape. The company recorded worldwide net sales of $220 million, marking a year-over-year decline, yet also presenting an encouraging operating income. Sales...

Continue Reading
Exciting UPCX Global Staking Opportunity with Major Rewards

Updated Category News Views 141

UPCX Limited-Time Staking Event Unveiled UPCX, an innovative blockchain financial services platform, proudly announces an engaging staking opportunity that is designed to foster user participation and spur innovation within its ecosystem. This exciting event invites users to take part in a limited-time stakes initiative, offering a significant reward pool of 4,900 UPC,...

Continue Reading
PepGen Inc. Shareholder Alert: Lawsuit Update and Key Details

Updated Category News Views 187

Update on the PepGen Inc. Class Action Lawsuit Levi & Korsinsky, LLP has taken significant steps to notify investors in PepGen Inc. of a class action securities lawsuit aimed at protecting shareholders' interests. Investors should be aware that the lawsuit concerns allegations of securities fraud that impacted investors during a defined time frame. Understanding the Class...

Continue Reading
Synchronoss Technologies Engages Investors via Upcoming Events

Updated Category News Views 116

Synchronoss Technologies Engages Investors with Upcoming Conferences Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a renowned leader in Personal Cloud platforms, is set to make a significant impact at two investor conferences. The company's President and CEO, Jeff Miller, along with CFO, Louis Ferraro, are ready to share insights...

Continue Reading